

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
P07 43084

Total Pages in this Submission  
98

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**METHODS AND COMPOSITIONS FOR IMPROVING DIGESTION AND  
ABSORPTION IN THE SMALL INTESTINE**

and invented by:

**HENRY C. LIN**

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 09/359,583

Which is a:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/832,307

Which is a:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/442,843

Enclosed are:

### Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 52 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☒ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
P07 43084

Total Pages in this Submission  
**98**

**Application Elements (Continued)**

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☐ Formal      b. ☐ Informal      Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)*      ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☐ With Power of Attorney      ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference *(usable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☐ Genetic Sequence Submission *(if applicable, all must be included)*
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☐ Assignment Papers *(cover sheet & documents)*
9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449      ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class      ☒ Express Mail *(Specify Label No.):* 349 964 343 US

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
P07 43084

Total Pages in this Submission  
98

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Small Entity Statement(s) - Specify Number of Statements Submitted: 1
17. ☒ Additional Enclosures (please identify below):

POWER OF ATTORNEY (COPY)  
ASSOCIATE POWER OF ATTORNEY (COPY)

**Fee Calculation and Transmittal**


**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	95	- 20 =	75	x \$9.00	\$675.00
Indep. Claims	19	- 3 =	16	x \$39.00	\$624.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$380.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$1,679.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 16-2460 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated:

18 October 1999

  
Signature

Nisan A. Steinberg, Ph.D., Registration No. 40,345  
PRETTY, SCHROEDER & POPLAWSKI, P.C.  
444 South Flower Street - 19th Floor  
Los Angeles, CA 90071-2909  
Ofc: 213/622-7700  
Fax: 213/489-4210

CC:

EXECUTED VERIFIED STATEMENT  
(DECLARATION)  
CLAIMING SMALL ENTITY STATUS  
DOCKET NO.: P07 33580  
SERIAL NO.: 08/442,843

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, Box PATENT APPLICATION on August 15, 1995.

By: Deborah A. Dugan  
Deborah A. Dugan, Reg No. 37,315

08/15/95  
Date of Signature

008101: 9400460

Applicant or Patentee: Henry C. Lin, M.D.

Serial No. or Patent No.: 08/442,843

Filed or Issued: May 17, 1995

Title: METHODS AND COMPOSITIONS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 C.F.R. §§1.9(f) and 1.27(d) - NONPROFIT ORGANIZATION)**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION **CEDARS-SINAI MEDICAL CENTER**  
 ADDRESS OF ORGANIZATION **8700 BEVERLY BLVD.**  
**LOS ANGELES, CALIFORNIA 90048-1865**

**TYPE OF ORGANIZATION**

- ☐ University or other Institution of Higher Education  
☒ Tax Exempt under Internal Revenue Service Code (26 U.S.C. §§501(a) and 501(c) (3))  
☐ Nonprofit Scientific or Educational under Statute of State of the United States of America (Name of State \_\_\_\_\_)  
 (Citation of Statute \_\_\_\_\_)  
☐ Would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§501(a) and 501(c) (3)) if located in the United States of America  
☐ Would qualify as nonprofit Scientific or Educational under Statute of State of the United States of America if located in the United States of America (Name of State \_\_\_\_\_)(Citation of Statute \_\_\_\_\_)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled METHODS AND COMPOSITIONS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE by inventor(s) HENRY C. LIN described in:

- ☐ the specification filed herewith  
☒ application Serial No. 08/442,843, filed May 17, 1995  
☐ Patent No. \_\_\_\_\_, issued \_\_\_\_\_

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. §1.9(d) or a nonprofit organization under 37 C.F.R. §1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 C.F.R. §1.27).


Full Name \_\_\_\_\_  
 Address \_\_\_\_\_  
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization  
 Full Name \_\_\_\_\_  
 Address \_\_\_\_\_  
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization  
 Full Name \_\_\_\_\_  
 Address \_\_\_\_\_  
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. §1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Peter E. Braveman, Esq.  
 TITLE IN ORGANIZATION Vice President for Legal Affairs  
 ADDRESS OF PERSON SIGNING 8700 Beverly Blvd., Los Angeles, California

90048-1865

SIGNATURE  DATE 3 August 1995

APPLICATION

for

UNITED STATES LETTERS PATENT

on

METHODS AND COMPOSITIONS FOR IMPROVING DIGESTION AND  
ABSORPTION IN THE SMALL INTESTINE

by

Henry C. Lin, M.D.

Number of Drawings: 0

Docket No.: P07 43084

Attorneys

Pretty, Schroeder & Poplawski, P.C.  
444 South Flower Street, Suite 2000  
Los Angeles, California 90071

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER EL 349 964 343 US  
DATE OF DEPOSIT OCTOBER 18, 1999

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES  
POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1-10 ON  
THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX NEW PATENT APPLICATION, THE  
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D. C. 20231.

Laura A. Brown  
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)  
Laura A. Brown  
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

# METHODS AND COMPOSITIONS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE

This application is a continuation-in-part of U.S. Patent Application Serial  
No. 09/359,583, filed on July 22, 1999, which is a continuation of U.S. Patent  
5 Application Serial No. 08/832,307, filed on April 3, 1997, which is a continuation of U.S.  
Patent Application Serial No. 08/442,843, filed on May 17, 1995.

## FIELD OF THE INVENTION

The present invention relates to methods and pharmaceutical compositions  
for controlling the presentation of luminal content in the gastrointestinal tract.

10

## BACKGROUND OF THE INVENTION

A principal function of the gastrointestinal tract is to process and absorb  
food. The stomach, which is both a storage and digestive organ, works to optimize the  
conditions for the digestion and absorption of food in the small intestine. Following the  
stomach and preceding the large bowel (colon) is the small intestine, which comprises  
15 three regions: the duodenum, jejunum, and ileum. A major function of the small intestine  
is one of absorption of digested nutrients.

The passage of a meal through the gastrointestinal tract, which leads to  
digestion and absorption of nutrients, is controlled by a complex system of inhibitory and  
stimulatory motility mechanisms which are set in motion by the composition of the meal  
20 ingested. Specific receptors for fats and proteins, and the osmolality, acidity and particle  
size of the meal activate propulsive and inhibitory reactions, which modulate transit and  
thus absorption. In normal human subjects, the mechanisms that regulate gastrointestinal  
transit can, under some circumstances, be sensitized or desensitized in response to the  
subject's recent dietary history. (K.M. Cunningham *et al.*, *Gastrointestinal adaptation*  
25 *to diets of differing fat composition in human volunteers*, Gut 32(5):483-86 [1991]).

The rate of transit through the small intestine is of great significance for  
the rate and extent of absorption from the small intestine. Disruption of the normal

digestive and absorptive processes frequently manifests as a variety of syndromes, such as, for example malnutrition, weight loss, diarrhea, steatorrhea, vitamin deficiency, electrolyte imbalance, and the like. Chronic diarrhea is a common problem found in a variety of gastrointestinal disorders where water, solutes and nutrients are malabsorbed

5 (Read, N.W., Diarrhee motrice, Clin. Gastroenterol. 15: 657-86 [1986]). Specifically, conditions such as short bowel syndrome, postgastrectomy dumping and ileal resection may lead to symptoms such as postprandial distension, cramping, abdominal pain, gaseousness, nausea, palpitations, flushing, steatorrhea or weight loss. These symptoms may persist despite the use of anti-diarrheal medications, anticholinergic agents (Ivey, KJ., *Are anticholinergics of use in the irritable bowel syndrome?*, Gastroenterology 68: 1300-07 [1975]), somatostatin analogues (Reasbeck PG, and AM Van Rij, *The effect of somatostatin on dumping after surgery: A preliminary report*, Surgery 1986; 99: 462-468 [1986]), conjugated bile acid replacement therapy (C. Gruy-Kapral *et al.*, *Conjugated bile acid replacement therapy for short-bowel syndrome*, Gastroenterol. 116:15-21 [1999]),

15 or large quantities of opiates (O'Brien, J.D. *et al.*, *Effect of codeine and loperamide on upper intestinal transit and absorption in normal subjects and patients with postvagotomy diarrhea*, Gut 19: 312-18 [1988]). Additionally, even with treatment, fecal loss of water, solutes and nutrients may still be so excessive in some patients that long term use of parenteral fluids and nutrition may be required for survival (Rombeau, J.L. and R.H. Rolandelli, *Enteral and parenteral nutrition in patients with enteric fistulas and short bowel syndrome*, Surg. Clin. North Am. 67:551-571 [1989]).

20

The small intestine is also an important site for the absorption of pharmacological agents. The proximal part of the small intestine has the greatest capacity for absorption of drugs. Intestinal absorption of drugs is influenced to a great extent by

25 many of the same basic factors that affect the digestion and absorption of nutrients, water and electrolytes.



Absorption of a drug in the gastrointestinal tract is a function of characteristics of the drug, such as its molecular structure, as well as attributes of the gastrointestinal tract. The rate of absorption of certain drugs, which are absorbed slowly and usually incompletely, varies according to the small intestinal transit time. Intestinal transit is important in the design of pharmaceutical preparations, especially when the absorption site of a drug is located in a particular segment of the gastrointestinal tract.

Many drugs and dosage formulations have been and continue to be developed because of the need to overcome the physiological and physicochemical limitations associated with drug delivery such as poor stability, short biological half-life, inefficient absorption and poor bioavailability. Applications of controlled release technology have moved towards control of absorption via regulation of the input to the gastrointestinal tract. However, recent pharmaceutical attempts to alter gastric emptying and small intestinal transit times have not been very successful. (Khosla and Davis, *J. Pharm. Pharmacol.* 39:47-49 [1987]; Davis *et al.*, *Pharm. Res.* 3:208-213 [1986]).

For drug absorption to proceed efficiently, the drug must first arrive at a normal absorbing surface in a form suitable for absorption; it must remain there long enough in a form and in a concentration that enhance absorption; and it must be absorbed by a normal epithelial cell without being metabolized by that cell. Accordingly, considerable advantage would be obtained if a pharmaceutical dosage form could be retained for a longer period of time within the stomach and/or the small intestine for proper absorption to occur.

The period of time during which nutrients and/or drugs are in contact with the mucosa of the small intestine is crucial for the efficacy of digestion and absorption. Inadequate residence time can lead to fecal loss of nutrients and diarrhea. Therefore, modulation of the motility rate and transit time of nutrients and/or pharmacologically active agents through the gastrointestinal tract will ensure optimal utilization of the absorptive surface, as well as prevent transport mechanisms from being overloaded

(which could occur if substrates were passed on too rapidly and exceeded the absorptive capacity of already maximally loaded surfaces in the small intestine).

5 The speed of transit through the small intestine is normally regulated by inhibitory mechanisms located in the proximal and distal small intestine known as the jejunal brake and the ileal brake. Inhibitory feedback is activated to slow transit when end products of digestion make contact with nutrient sensors of the small intestine. Specifically, jejunal and ileal brakes slow transit by the release of gut peptides such as peptide YY and by the activation of neural pathways such as those involving endogenous opioids. Transit is then slowed by the stimulation of nonpropagative intestinal  
10 contractions which inhibit movement of the luminal content. The removal or impairment of these inhibitory mechanisms can lead to abnormally rapid transit. For example, in patients with a history of resection of the terminal ileum, intestinal transit may become uncontrolled and abnormally accelerated when the ileal brake is no longer intact. Time for processing of food may then be so reduced that few end products of digestion are  
15 available to trigger the jejunal brake as the remaining inhibitory mechanism.

Thus, a need exists for optimizing absorption of ingested nutrients and/or pharmacologically active agents in the small intestine to prevent and/or reduce ineffectiveness thereof due to malabsorption. A need also exists for means to enhance the bioavailability and effectiveness of pharmacologically active agents. The present  
20 invention satisfies these needs and provides related advantages as well.

#### SUMMARY OF THE INVENTION

The present invention provides methods and compositions for slowing gastrointestinal transit and prolonging residence time to optimize presentation and absorption of ingested nutrients and/or pharmacologically active agents in the small  
25 intestine to prevent and/or reduce ineffectiveness thereof due to malabsorption.

The present invention further provides methods and compositions for enhancing the bioavailability and therapeutic effectiveness of pharmacologically active agents.

#### DETAILED DESCRIPTION OF THE INVENTION

5           Important steps in dietary lipid absorption begin in the stomach, where an intricate control system of inhibitory and stimulatory motility mechanisms are set in motion by the composition of the meal ingested. These mechanisms prevent too rapid emptying of gastric contents into the duodenum, which would overwhelm its capacity for lipid or fat absorption. Such preventative mechanisms ensure a maximum interface of  
10   the water-insoluble lipid with the aqueous contents of the intestinal tract.

          The next step in absorption of fats or lipids occurs upon their entry into the small intestine. In the early portion of the small intestine, specific receptors for fats and proteins, and the osmolality, acidity and the particle size of the meal activate propulsive and inhibitory reactions (i.e., ileal braking), which modulate their transit and  
15   absorption. The rate of passage through the small intestine (i.e., intestinal transit time) is of great significance for the rate and extent of absorption from the small intestine.

          In the duodenum, the fats which have been released from the stomach encounter bile acids and pancreatic enzymes. The function of the bile acids is to render soluble the insoluble triglyceride molecules.

20           The intestinal absorption of lipids is normally very efficient over wide ranges of dietary fat intake. A normal person generally absorbs approximately 95-98% of dietary lipid. When the normal digestive and absorptive processes are impaired, malabsorption syndromes frequently ensue.

          Malabsorption syndromes include a large heterogeneous group of  
25   gastrointestinal disorders with the common characteristic of failure to assimilate ingested substances normally. The defect is characterized by decreased or impaired function of

almost any organ of the gut, including the liver, biliary tract, pancreas, and lymphatic system, as well as the intestine. The clinical manifestations may vary from a severe symptom complex of rapid intestinal transit, dumping syndrome, diarrhea, weight loss, distention, steatorrhea, and asthenia to symptoms of specific nutrient deficiencies (i.e.,  
5 malnutrition).

Examples of gastrointestinal disorders that frequently manifest as one or more malabsorption syndromes are postgastrectomy syndrome, dumping syndrome, AIDS-associated chronic diarrhea, diabetes-associated diarrhea, postvagotomy diarrhea, bariatric surgery-associated diarrhea (including obesity surgeries: gastric bypass,  
10 gastroplasties and intestinal bypass), short bowel syndrome (including resection of the small intestine after trauma, radiation induced complications, Crohn's disease, infarction of the intestine from vascular occlusion), tube-feeding related diarrhea, chronic secretory diarrhea, carcinoid syndrome-associated diarrhea, gastrointestinal peptide tumors, endocrine tumors, chronic diarrhea associated with thyroid disorders, chronic diarrhea in  
15 bacterial overgrowth, chronic diarrhea in gastrinoma, choleraic diarrhea, chronic diarrhea in giardiasis, antibiotic-associated chronic diarrhea, diarrhea-predominant irritable bowel syndrome, chronic diarrhea associated with maldigestion and malabsorption, chronic diarrhea in idiopathic primary gastrointestinal motility disorders, chronic diarrhea associated with collagenous colitis, surgery-associated acute diarrhea, antibiotic-  
20 associated acute diarrhea, infection-associated acute infectious diarrhea, and the like.

The rate at which food passes through the gastrointestinal tract is an important factor that affects the absorptive capacity and the outcome following gastric surgery and/or intestinal resection. Resection of extensive sections of bowel as well as loss of absorptive surface secondary to diseased small bowel mucosa can lead to specific  
25 malabsorption syndromes. Resection or disease of large amounts of terminal ileum are known to cause vitamin B12 and bile acid deficiencies, which, in turn, can lead to fat and other fat-soluble substances being less well absorbed. Bypassed loops of bowel, created by either surgery or fistula formation, and strictures can result in blind loop syndromes with bacterial overgrowth and subsequent malabsorption.

Malnutrition is a common problem in patients with inflammatory bowel diseases such as, for example, Crohn's disease or ulcerative colitis. Weight loss is found in 70-80% of patients with Crohn's disease and 18-62% of patients with ulcerative colitis.

5 The role of nutritional support as a primary therapy for inflammatory bowel diseases is not well established. Given the natural history of inflammatory bowel diseases, with frequent relapses and spontaneous remissions, and the difficulty and variability in quantifying disease activity, it has been difficult to design clinical trials that definitively establish the role of nutrition as a primary therapy for inflammatory bowel diseases. The use of elemental diets as primary therapy for inflammatory bowel diseases  
10 has also been examined. Parenteral nutrition and elemental diets appear to have limited roles in the long-term treatment of patients with inflammatory bowel diseases.

Short bowel syndrome generally refers to a condition in which less than 150 cm of remaining small bowel is associated with a massive loss of absorptive capacity. It is characterized by severe diarrhea and malabsorption. Patients with short  
15 bowel syndrome often experience malabsorption of protein, carbohydrate and fat resulting in calorie depletion and steatorrhea.

The most important therapeutic objective in the management of short bowel is to maintain the patient's nutritional status. By necessity, it is achieved primarily by parenteral nutrition support in the early postoperative period. Enteral nutrition support  
20 can be started early after operation when the ileus has resolved. Maximization of enteral absorption of nutrients is important for long-term survival. Generally, such maximization requires that the enteral intake greatly exceed the absorptive needs to ensure that the nutritional requirements are met.

Functional pancreatic insufficiency may also cause steatorrhea after gastric  
25 resection. Steatorrhea is the presence of excess fat in the feces. It is usually caused by a defect in gastrointestinal digestion and/or absorption. Steatorrhea rarely exists without malabsorption of other substances. For example, conditions such as osteomalacia related

to calcium and vitamin D deficiency or anemia due to selective iron or B12 deficiencies are often associated with the malabsorption that occurs with steatorrhea. Weight loss occurs because of a loss of nutrients and energy. Diarrhea is another major symptom associated with steatorrhea. It is present in 80-97% of patients with malabsorption.

5                      Dumping syndrome is one of the most common causes of morbidity after gastric surgery. This syndrome is characterized by both gastrointestinal and vasomotor symptoms. Gastrointestinal symptoms include postprandial fullness, crampy abdominal pain, nausea, vomiting and explosive diarrhea. Vasomotor symptoms include, diaphoresis, weakness, dizziness, flushing, palpitations, and an intense desire to lie down.

10      Patients with severe dumping symptoms may limit their food intake to minimize symptoms and as a result lose weight and become malnourished. In severe cases, as a last resort surgical treatment of dumping syndrome has been utilized.

Pharmaceutical treatment for severe dumping includes octreotide acetate (Sandoz), a long acting somatostatin analogue, which has been used with some success.

15      Octreotide is administered subcutaneously and acts to slow gastric emptying, inhibit insulin release, and decrease enteric peptide secretion. Octreotide, unfortunately, is accompanied by several complications, which include injection site pain, tachyphylaxis, iatrogenic diabetes, malabsorption and cholelithiasis.

Diarrhea is a common problem after any abdominal operation. Treatment  
20      includes simple dietary changes, opiates and/or opiod-type drugs such as Lomotil or paregoric, antidiarrheal agents such as Diasorb (attapulgate), Donnagel (kaolin, hydroscymine sulfate, atropine sulfate and scopolamine hydrobromide), Kaopectate, Motofen (difenoxin hydrochloride and atropine sulfate) and Pepto-Bismol for inhibitory effect on intestinal transit. Each modality of treatment, however, has had limited success  
25      and with the exception of dietary changes, all have negative side effects associated with use.

Diarrhea is also a common complication associated with enteral feeding. Multiple etiologies for diarrhea are postulated, and its genesis may be a multifactorial process (Edes et al., *Am. J. Med.* 88:91-93 (1990)). Causes include concurrent use of antibiotics or other diarrhea-inducing medications, altered bacterial flora, formula composition, rate of infusion, hypoalbuminemia, and enteral formula contamination. The composition of formula may also affect the incidence of diarrhea. The use of fiber-containing formulas to control diarrhea related to tube feeding is unsettled (Frankenfield et al., *Am. J. Clin. Nutr.* 50:553-558 [1989]).

A tremendous amount of research has been undertaken in attempting to elucidate the role of nutrition and absorption in gastrointestinal disorders. Despite this research, few standards of care presently exist for the use of nutrition and absorption in most aspects of these disorders.

Accordingly, the present invention provides methods of slowing gastrointestinal transit to prolong the residence time of a substance in the small intestine of a subject for an amount of time sufficient for digestion and absorption of the substance to occur therein. Invention methods comprise administering to a subject a composition comprising an active lipid in an amount effective to slow the transit of said substance through the small intestine for an amount of time sufficient for absorption of said substance to occur therein.

The invention contemplates a range of optimal residence times which are dependent upon the character of the substance (i.e., nutrients, pharmacologically active agents). As used herein, "substance" encompasses the luminal content of the gastrointestinal tract which includes, for example, digested and partially digested foods and nutrients, dissolved and/or solubilized pharmacologically active agents as well as incompletely dissolved and/or solubilized forms thereof, electrolyte-containing luminal fluids, and the like.

5 The small intestinal residence time for optimal absorption of digested foods and nutrients can be calculated using an average orocecal transit time as a reference. The normal orocecal transit time is approximately 2-3 hours in the fasted state. The inventive composition should target an intestinal residence within the same average time frame of approximately 2-3 hours.

10 The pharmaceutical industry has published a great deal of information on the dissolution time for individual pharmacologically active agents and compounds. Such information is found in the numerous pharmacological publications which are readily available to those of skill in the art. For example, if the *in vitro* model for dissolution and release of agent "X" is 4 hours, then the small intestinal residence time for optimal absorption of agent "X" would be at least 4 hours and would also include additional time allowing for gastric emptying to occur *in vivo*. Thus, for pharmacologically active agents, the appropriate residence time is dependent on the time for release of the active agent.

15 As used herein, "digestion" encompasses the process of breaking down large molecules into their smaller component molecules.

As used herein, "absorption" encompasses the transport of a substance from the intestinal lumen through the barrier of the mucosal epithelial cells into the blood and/or lymphatic systems.

20 As used herein, "pharmacological agent" encompasses any substance used to treat a disorder, abnormal condition, discomfort, wound, lesion, or injury, of a physical, biochemical, mental, emotional or affective nature. Examples of pharmacological agents include, but are not limited to, somatostatin analogues, insulin release inhibitors, anti-diarrheal agents, antibiotics, fiber, electrolytes, analgesics, antipyretics, migraine treatment, migraine prophylaxis, antifungal agents, antiviral agents, Quinolones, AIDS therapeutic agents, anti-infectives, aminoglycosides, antispasmodics, parasympathomimetics, anti-tuberculous agents, anti-malarial agents, accines, anti-parasitic agents, cephalosporins, macrolides, azalides, tetracyclines, penicillins, anti-





The inventive compositions comprise an active lipid and a pharmaceutically acceptable carrier. A major function of the inventive compositions is to slow gastrointestinal transit and control gastrointestinal intestinal residence time of a substance to enable substantial completion of lumenal and mucosal events required for absorption of the substance to occur in the small intestine. Of equal significance is the function of the inventive compositions to control the presentation of a substance to a desired region of the small intestine for absorption.

In a preferred embodiment, the inventive compositions limit the presentation of a substance to the proximal region of the small intestine for absorption.

As used herein, "active lipid" encompasses a digested or substantially digested molecule having a structure and function substantially similar to a hydrolyzed end-product of fat digestion. Examples of hydrolyzed end products are molecules such as glycerol and fatty acids.

In a preferred embodiment, the active lipid comprises a saturated or unsaturated fatty acid. Fatty acids contemplated by the invention include fatty acids having between 4 and 24 carbon atoms.

Examples of fatty acids contemplated for use in the practice of the present invention include caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, linolenic acid, *trans*-hexadecanoic acid, elaidic acid, columbinic acid, arachidic acid, behenic acid eicosenoic acid, erucic acid, bressidic acid, cetoleic acid, nervonic acid, Mead acid, arachidonic acid, timnodonic acid, clupanodonic acid, docosahexaenoic acid, and the like. In a preferred embodiment, the active lipid comprises oleic acid.

Also preferred are active lipids in the form of pharmaceutically acceptable salts of hydrolyzed fats, including salts of fatty acids. Sodium or potassium salts are preferred, but salts formed with other pharmaceutically acceptable cations are also useful.



incorporated into capsules, or a microsphere or particle (coated or not) contained in a capsule.

The compositions of the invention containing the active lipid may be in a form suitable for oral or enteral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs or enteral formulas. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Compositions may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, to form osmotic therapeutic tablets for controlled release. Other techniques for controlled release compositions, such as those described in the U.S. Pat. Nos. 4,193,985; and 4,690,822; 4,572,833 may be used in the formulation of the inventive compositions.

An effective amount of active lipid is any amount that is effective to slow gastrointestinal transit and control presentation of a substance to a desired region of the small intestine. For example, an effective amount of active lipid, as contemplated by the instant invention, is any amount of active lipid that can trigger any or all of the following reflexes: intestino-lower esophageal sphincter (relaxation of LES); intestino-gastric feedback (inhibition of gastric emptying); intestino-intestinal feedback (ileo-jejunal feedback/ileal brake, jejuno-jejunal feedback/jejunal brake, intestino-CNS feedback (for example, intensifying intestinal signalling of satiety`); intestino-pancreatic feedback (control of exocrine enzyme output); intestino-biliary feedback (control of bile flow); intestino-mesenteric blood flow feedback (for the control of mucosal hyperemia); intestino-colonic feedback (so called gastro-colonic reflex whereby the colon contracts in response to nutrients in the proximal small intestine).

Methods of administration are well known to those of skill in the art and include, but are not limited to oral administration, parenteral administration and enteral administration. In a preferred embodiment, the composition of the invention is administered in a load-dependent manner which ensures that the dispersion of active lipid

is presented to the entire length of the small intestine. Administration is in one or more doses such that the desired effect is produced. In some preferred embodiments, the load of active lipid per dose is from about 0.5 grams to about 2.0 grams, but can range up to about 25 grams per dose as needed. Generally, patients respond well to the most preferred amount of active lipid, which is in the range of about 1.6 to 3.2 grams. For patients who fail to respond to this dose range, a dose between 6 and 8 grams is typically effective.

In order to stretch biologic activity so that one has a convenient, daily dosage regimen, the present invention contemplates that the inventive compositions are administered prior to ingestion of the food, nutrient and/or pharmacologically active agent. In a preferred embodiment, the inventive compositions (depending on the formulation) are administered up to a period of 24 hours prior to ingestion of the food, nutrient and/or pharmacologically active agent, but most preferably between about 60 to 5 minutes before ingestion. The period of time prior to ingestion is determined on the precise formulation of the composition. For example, if the formulation incorporates a controlled release system, the duration of release and activation of the active lipid will determine the time for administration of the composition. Sustained release formulation of the composition is useful to ensure that the feedback effect is sustained.

Sequential dosing is especially useful for patients with short bowel syndrome or others with abnormally rapid intestinal transit times. In these patients, the first preprandial administration of the active lipid occurs in a condition of uncontrolled intestinal transit that can fail to permit optimal effectiveness of the active lipid. A second (or more) preprandial administration(s) timed about fifteen minutes after the first or previous administration and about fifteen minutes before the meal enhances the patient's control of intestinal lumenal contents and the effectiveness of the active lipid agent in accordance with the inventive methods. Normalization of nutrient absorption and bowel control throughout the day, including during the patient's extended sleeping hours, is best achieved by a dietary regimen of three major meals with about five snacks interspersed between them, including importantly, a pre-bedtime snack; administration

of a dose of the inventive composition should occur before each meal or snack as described above.

Treatment with the inventive compositions in accordance with the inventive methods can be of singular occurrence or can be continued indefinitely as needed. For example, patients deprived of food for an extended period (e.g., due to a surgical intervention or prolonged starvation), upon the reintroduction of ingestible food, may benefit from administration of the inventive compositions before meals on a temporary basis to facilitate a nutrient adaptive response to normal feeding. On the other hand some patients, for example those with surgically altered intestinal tracts (e.g., ileal resection), may benefit from continued pre-prandial treatment in accordance with the inventive methods for an indefinite period. However, clinical experience with such patients for over six years has demonstrated that after prolonged treatment there is at least a potential for an adaptive sensory feedback response that may allow them to discontinue treatment for a number of days without a recurrence of postprandial diarrhea or intestinal dumping.

The use of compositions of the present invention in enteral feeding contemplates adding the composition directly to the feeding formula. The composition can either be compounded as needed into the enteral formula when the rate of formula delivery is known (i.e., add just enough composition to deliver the load of active lipids). Alternatively, the composition of the invention can be compounded at the factory so that the enteral formulas are produced having different concentrations of the composition and can be used according to the rate of formula delivery (i.e., higher concentration of composition for lower rate of delivery).

If the inventive composition were to be added to an enteral formula and the formula is continuously delivered into the small intestine, the composition that is initially presented with the nutrient formula would be slowing the transit of nutrients that are delivered later. Except for the start of feeding when transit may be too rapid because

the inhibitory feedback from the composition has yet to be fully activated, once equilibrium is established, it is no longer logistically an issue of delivering the composition as a premeal although the physiologic principle is still the same.

Before dietary fats can be absorbed, the motor activities of the small intestine in the postprandial period must first move the output from the stomach to the appropriate absorptive sites of the small intestine. To achieve the goal of optimizing the movement of a substance through the small intestine, the temporal and spatial patterns of intestinal motility are specifically controlled by the nutrients of the luminal content.

Without wishing to be bound by any theory, it is presently believed that early in gastric emptying, before inhibitory feedback is activated, the load of fat entering the small intestine may be variable and dependent on the load of fat in the meal. Thus, while exposure to fat may be limited to the proximal small bowel after a small load, a larger load, by overwhelming more proximal absorptive sites, may spill further along the small bowel to expose the distal small bowel to fat. Thus, the response of the duodenum to fat limits the spread of fat so that more absorption can be completed in the proximal small intestine and less in the distal small intestine. Furthermore, since the speed of movement of luminal fat must decrease when more fat enters the duodenum, in order to avoid steatorrhea, intestinal transit is inhibited in a load-dependent fashion by fat. This precise regulation of intestinal transit occurs whether the region of exposure to fat is confined to the proximal gut or extended to the distal gut.

In accordance with the present invention it has been observed that inhibition of intestinal transit by fat depends on the load of fat entering the small intestine. More specifically, that intestinal transit is inhibited by fat in a load-dependent fashion whether the nutrient is confined to the proximal segment of the small bowel or allowed access to the whole gut.

Accordingly, the present invention provides a method of slowing gastrointestinal transit in a subject having a gastrointestinal disorder, said method

comprising administering to said subject a composition comprising an active lipid in an amount sufficient to prolong the residence time of a substance in the small intestine.

Invention methods and compositions are useful in the management of nutritional and absorption in subjects having a variety of gastrointestinal symptoms such as, rapid intestinal transit, dumping syndrome, diarrhea, weight loss, distention, steatorrhea, and asthenia to symptoms of specific nutrient deficiencies (i.e., malnutrition).

Examples of gastrointestinal disorders that invention methods and compositions are therapeutic include postgastrectomy syndrome, dumping syndrome, AIDS-associated chronic diarrhea, diabetes-associated diarrhea, postvagotomy diarrhea, bariatric surgery-associated diarrhea (including obesity surgeries: gastric bypass, gastroplasties and intestinal bypass), short bowel syndrome (including resection of the small intestine after trauma, radiation induced complications, Crohn's disease, infarction of the intestine from vascular occlusion), tube-feeding related diarrhea, chronic secretory diarrhea, carcinoid syndrome-associated diarrhea, gastrointestinal peptide tumors, endocrine tumors, chronic diarrhea associated with thyroid disorders, chronic diarrhea in bacterial overgrowth, chronic diarrhea in gastrinoma, choleraic diarrhea, chronic diarrhea in giardiasis, antibiotic-associated chronic diarrhea, diarrhea-predominant irritable bowel syndrome, chronic diarrhea associated with maldigestion and malabsorption, chronic diarrhea in idiopathic primary gastrointestinal motility disorders, chronic diarrhea associated with collagenous colitis, surgery-associated acute diarrhea, antibiotic-associated acute diarrhea, infection-associated acute infectious diarrhea, and the like.

The instant invention further provides a method and composition for treating diarrhea in a subject, said method comprising administering to said subject a composition comprising an active lipid in an amount sufficient to prolong the residence time of the luminal contents of the small intestine. The inventive composition can be delivered as a single unit, multiple unit (for more prolonged effect via enterically coated or sustained release forms) or in a liquid form.



Since cholesterol and triglycerides are so insoluble in plasma, after mucosal absorption of lipids, the transport of these lipids from the intestine to the liver occurs through lipoproteins called chylomicrons.

While fat absorption from the lumen is rate-limiting for the proximal half of the small intestine, chylomicron synthesis or release is rate-limiting for the distal one half of the small intestine. As a result, chylomicrons formed by the distal small intestine are larger than those from the proximal small intestine (Wu, 1975). In the capillary bed of the peripheral circulatory system, the enzyme lipoprotein lipase hydrolyzes and removes most of the triglycerides from the chylomicron. The lipoprotein that remains, now rich in cholesterol esters and potentially atherogenic, is called a chylomicron remnant. This postprandial lipoprotein is then removed from the circulation by the liver (Zilversmit, *Circulation* 60(3):473 [1979]).

Elevated levels of atherogenic serum lipids have been directly correlated with atherosclerosis (Keinke *et al.*, *Q. J. Exp. Physiol.* 69:781-795 [1984]).

The present invention provides a novel method to minimize atherogenic postprandial lipemia by optimizing proximal fat absorption. In other words, the present invention provides a novel method by which atherogenic serum lipids can be controlled preabsorptively by the fed motility response of the small intestine to lumenal fat.

Preabsorptive control depends on the triggering of a specific pattern of proximal intestinal motility which slows transit to minimize the spread of fat into the distal gut. After a small meal of cholesterol-containing, fatty foods, the small intestine limits the site of fat absorption to the proximal small intestine by generating nonpropagated motility to slow intestinal transit. Since chylomicrons produced by the proximal small intestine are small in size, the size distribution of postprandial lipoproteins is shifted to minimize postprandial lipemia. However, during gorging of a high cholesterol, high fat meal, the ability of the small intestine to optimize proximal fat absorption is reduced by the time-dependent fading of the effect of fat on nonpropagated

motility. As a result, after the first 1-2 hours, faster intestinal transit works to displace luminal fat into the distal small intestine where large, cholesterol-enriched, atherogenic chylomicrons are formed and released into the circulation.

In addition to the dietary effects on intestinal transit, studies suggest that nicotine inhibits intestinal motility. (McGill [1979]; Maida [1990]) (Booyse [1981]) (Carlson [1970]). In the postprandial situation, this nicotine-related inhibitory effect alters the potentially protective, braking or nonpropagated pattern of motility. As a result, nicotine may facilitate the spreading of ingested lipids into the distal small intestine and impair the preabsorptive control of lipids. The methods of the present invention provide means to minimize the nicotine-induced inhibition of this postprandial response and to maximize proximal fat absorption.

Oral pharmaceutical preparations account for more than 80% of all drugs prescribed. It is essential, therefore, to control the multiple factors that influence their intestinal absorption as a determinant of ultimate therapeutic effectiveness.

Disintegration and dissolution are factors determining drug absorption that takes place only after a drug is in solution. Drugs ingested in solid form must first dissolve in the gastrointestinal fluid before they can be absorbed, and tablets must disintegrate before they can dissolve. The dissolution of a drug in the gastrointestinal tract is often the rate-limiting step governing its bioavailability. In any given drug, there can be a 2- to 5-fold difference in the rate or extent of gastrointestinal absorption, depending on the dosage or its formulation.

The rate of gastric emptying bears directly on the absorption of ingested drugs and on their bioavailability. Some drugs are metabolized or degraded in the stomach, and delayed gastric emptying reduces the amount of active drug available for absorption.

The pharmaceutical industry has developed all sorts of slow and/or

sustained-release technology. These efforts have been directed to delaying gastric emptying. Sustained-release formulations employ several methods. The most common is a tablet containing an insoluble core; a drug applied to the outside layer is released soon after the medication is ingested, but drug trapped inside the core is released more slowly. Capsules containing multiparticulate units of drug with coatings that dissolve at different rates are designed to give a sustained-release effect. However, the basic problem with sustained-release medications is the considerable variability in their absorption due to the inability to monitor the individual's ingestion of the medication and thus, inability to control transit. Accordingly, slow release of drug in the absence of slow transit in the gut is meaningless.

The instant invention solves the bioavailability problem in this instance. The methods and compositions of this invention enable one to manipulate the balance of dissolution and gastrointestinal transit by increasing gastrointestinal residence time.

To facilitate drug absorption in the proximal small intestine, the present invention provides a method for prolonging the gastrointestinal residence time which will allow drugs in any dosage form to more completely dissolve and be absorbed. Since the inventive compositions slow gastrointestinal transit (delays both gastric emptying and small intestinal transit) a more rapid dissolving dosage form is preferred.

Accordingly, the present invention provides pharmaceutical oral articles and enteral formulas that slow gastrointestinal transit and prolong residence time of a substance. The composition of the invention enhance dissolution, absorption, and hence bioavailability of pharmacologically active agents ingested concurrently therewith or subsequent thereto.

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains one or more of the compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or

excipient suitable for enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.

The active lipid is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of diseases.

Pharmaceutical compositions containing the active lipid may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs or enteral formulas. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the

techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, to form osmotic therapeutic tablets for controlled release. Other techniques for controlled release compositions, such as those described in the U.S. Pat. Nos. 4,193,985; and 4,690,822; 4,572,833 may be used in the formulation of invention pharmaceutical compositions.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

The methods and compositions of the invention are most needed for pharmacologically active agents that have slow dissolution characteristics. Since the active agent is released slowly such as formulations that are now enterically coated or packaged in a sustained release form, there is great potential for the drug to be passed into the colon still incompletely absorbed. The role of the inventive compositions is to increase the gastrointestinal residence time to allow the poorly dissolving drugs to be fully absorbed.

In one embodiment of the present invention, the pharmaceutical article is an enterically coated or a sustained release form that intestinal transit is slowed for a prolonged period of time. The pharmacologically active agent can also be packaged in an enterically coated or sustained release form so that it can also be released slowly. This combination would probably have the longest biologic activity and be favored if a high initial drug plasma peak is not desirable.

In an alternative embodiment, invention pharmaceutical article may be formulated for controlled release (enterically coated or sustained release form) whereas a rapid release formulation is contemplated for the pharmacologically active agent (tablet or capsule with rapid dissolution characteristics or composition in a liquid form). This simpler strategy would be used if the claimed composition is able to "hold" the active

drug in the proximal small intestine for a period long enough for complete absorption of the drug to take place and a high initial peak of the drug is desirable.

Another embodiment of the instant invention contemplates a rapid release formulation of the composition/article. This form would be administered following slow release of the pharmacologically active agent which is enterically coated or a sustained release form.

Also contemplated by the instant invention is the combination of a rapid release form of the composition/article and a rapid release of the pharmacologically active agent.

Accordingly, the methods and compositions of the instant invention can be combined with the existing pharmaceutical release technology to provide control over not only the gastrointestinal transit and residence time of a pharmacologically active agent, but also over the time of release of the active agent. More specifically, the combination of invention methods and compositions with existing release technology provides control over the multiple factors that influence intestinal absorption of a pharmacologically active agent. The ability to control such factors enables optimization of the bioavailability and ultimate therapeutic effectiveness of any pharmacologically active agent.

The following examples are intended to illustrate, but not limit, the present invention.

## EXAMPLE I

### Oleate and Oleic Acid Slow Upper Gut Transit and Reduce Diarrhea in Patients with Rapid Upper Gut Transit and Diarrhea

Rapid transit through the upper gut may result in diarrhea, maldigestion and absorption, and weight loss; and pharmacologic treatment with opiates or anticholinergics often is required. It was tested whether fatty acids could be used to slow upper gut transit and reduce diarrhea in patients with rapid transit and diarrhea.

In a preliminary study, five patients with persistent diarrhea for 3 to 22 months, (one each due to vagal denervation, ileal resection for Crohn's disease, and vagotomy and antrectomy, and two due to idiopathic causes) were studied. Each patient demonstrated rapid upper gut transit on routine lactulose breath hydrogen testing (or variations thereof measuring labelled carbon dioxide)(Cammack *et al. Gut* 23:957-961 [1982]). This test relies on the metabolism of certain carbohydrate materials (e.g. lactulose) by the microbial flora within the caecum. By generating gas which can be detected in the expired air, it is possible to make some estimation about the initial arrival of the administered material within the colon.

Each patient received orally in random order, 0, 1.6 or 3.2 g of sodium oleate in 25 mL Ensure (Ross), followed by 100 mL water. Thirty minutes after each dose of oleate, patients received 10 g lactulose orally, followed by 25 mL water. Breath samples were collected in commercially available breath testing bags (Quintron, Menomonee Falls, WI) every 10-15 minutes, and the hydrogen content of the samples was measured using a breath analyzer (Microlyzer Model 12, Quintron Instruments, Menomonee Falls, WI), calibrated against gas samples of known hydrogen concentration. With a syringe, a 40-mL sample of the expired breath was withdrawn from the collection bag and analyzed immediately for hydrogen concentration (ppm). The hydrogen concentration value from each sample was plotted against time. Upper gut transit time was defined as the time in minutes from ingestion of lactulose ( $t_0$ ) until a rise of  $H_2$  of

>10 ppm. Data were further analyzed using 1-way repeated measures analysis of variance (ANOVA).

Results (mean  $\pm$  SE):

Oleate (g)	0	1.6	3.2
Transit time (min)	46 $\pm$ 8.6	116 $\pm$ 11.1	140 $\pm$ 11.5

Upper gut transit was significantly prolonged by oleate in a dose-dependent fashion ( $p < 0.005$ , significant trend). During prolonged ingestion of oleate 15-30 minutes prior to meals, all patients reported reduced diarrhea. The patient with Crohn's disease reported complete resolution of chronic abdominal pain as well as post prandial bloating and nausea, and gained 22 lbs. In addition, the patient with vagotomy and antrectomy reported resolution of postprandial dumping syndrome (flushing, nausea, light-headedness).

The effect of an active lipid on transit time was determined in 8 normal human subjects (1 male and 7 females with a mean age of  $35 \pm 2.6$  years [SE]) and 45 patients (20 males and 25 females with a mean age of  $49.1 \pm 2.5$  [SE], age range from 18 to 90 years) with chronic diarrhea (i.e., continuous diarrhea for more than two months) associated with a wide variety of diagnoses and conditions (e.g., Crohn's disease; irritable bowel syndrome; short bowel syndrome; Indiana pouch; AIDS; ulcerative colitis; vagotomy; antrectomy; ileostomy; partial and complete colectomy; colon cancer; diabetes mellitus type 1; pancreatic insufficiency; radiation enteropathy; esophagectomy/gastric pull-up; total and subtotal gastrectomy; gastorjejunostomy), made by referring gastroenterologists. The method was the same as described above, except oleic acid (Penta Manufacturing, Livingston, NJ) replaced sodium oleate in 50 mL of Ensure emulsion. All subjects refrained from taking antibiotics for at least two weeks before each testing date and during stool measurement periods. Patients were also instructed to refrain from anti-diarrheal drugs, laxatives, somatostatin analogues or anticholinergics for at least 48 hours before each test. In both the normal and patient groups, there was a significant slowing of upper gut transit time in response to oleic acid, as summarized below ( $p < 0.001$ ):



	<u>Transit time (min) (mean <math>\pm</math> SE)</u>		
<u>Oleic Acid (g)</u>	<u>0</u>	<u>1.6</u>	<u>3.2</u>
Normal	105.2 $\pm$ 12.1	116 $\pm$ 11.1	140 $\pm$ 11.5
Patients	29.3 $\pm$ 2.8	57.2 $\pm$ 4.5	83.3 $\pm$ 5.2

Continuing oleic acid treatment at home was offered to “responders” (i.e., patients who experienced a greater than 100 % increase in baseline transit time with 3.2 g oleic acid). Of the 36 responders out of the original 45 patients, 18 provided records of stool volume and frequency on- and off- treatment for comparison. The inconvenient and unappealing nature of stool collection and measurement were the primary reasons reported by responders who chose not to participate in stool collection. After completing a set of three preliminary breath hydrogen tests, each participating responder was asked to refrain from taking oleic acid for two days in order to measure off-treatment stool output for a 24-hour period. Patients were issued a stool pattern record form and a stool collection container with graduated volume markings to record the frequency and volume of bowel movements. After two days without oleic acid, each patient took 3.2 g of oleic acid mixed with 25 mL of Ensure emulsion three times a day, 30 minutes before breakfast, lunch and dinner. After taking oleic acid for two days, patients recorded stool output for another 24-hour period. With this oleic acid emulsion treatment, stool frequency decreased from  $6.9 \pm 0.8$  to  $5.4 \pm 0.9$  bowel movements per 24-hour period ( $p < 0.05$ ), and stool volume decreased from  $1829.0 \pm 368.6$  to  $1322.5 \pm 256.9$  per 24-hour period ( $p < 0.05$ ). A slight and transient burning sensation in the mouth or throat was the only adverse effect reported by any patient taking the oleic acid treatment.

These experiments demonstrate that active lipids, such as oleate and oleic acid, are effective in slowing upper gut transit in a dose-dependent manner and reduce diarrhea among patients with rapid transit and diarrhea. This novel treatment is effective in other chronic diarrheal conditions associated with rapid transit.

## EXAMPLE II

### Fat in Distal Gut Inhibits Intestinal Transit More Potently Than Fat in Proximal Gut

In 4 dogs equipped with duodenal (10 cm from pylorus) and midgut (160 cm from pylorus) fistulas, intestinal transit was compared across an isolated 150 cm test segment (between fistulas) while 0, 15, 30 or 60 mM oleate was delivered into either the proximal or distal segment of the gut as a solution of mixed micelles in pH 7.0 phosphate buffer at 2 mL/min for 90 minutes. The segment of gut not receiving oleate was perfused with buffer at 2 mL/min. 60 minutes after the start of the perfusion, ~20  $\mu$ Ci of  $^{99m}$ Tc-DTPA (diethylenetriaminepentaacetic acid) was delivered as a bolus into the test segment. Intestinal transit was then measured by counting the radioactivity of 1 ml samples collected every 5 minutes from the diverted output of the midgut fistula.

Intestinal transit was calculated by determining the area under the curve (AUC) of the cumulative percent recovery of the radioactive marker. The square root values of the AUC (Sqrt AUC), where 0 = no recovery by 30 minutes and 47.4 = theoretical, instantaneous complete recovery by time 0, were compared across region of fat exposure and oleate dose using 2-way repeated measures ANOVA.

Region of fat exposure	Oleate dose (mM) (mean $\pm$ SE)		
	15	30	60
Proximal 1/2 of gut	41.6 $\pm$ 1.4	40.6 $\pm$ 10.2	34.4 $\pm$ 3.0
Distal 1/2 of gut	25.6 $\pm$ 1.4	18.9 $\pm$ 1.5	7.0 $\pm$ 3.8

Control: buffer into both proximal and distal 1/2 of gut = 41.4  $\pm$  4.6.

These experiments demonstrate that intestinal transit is slower when fat is exposed in the distal 1/2 of gut (region effect  $p < .01$ ). These experiments also demonstrate that oleate is effective to inhibit intestinal transit in a dose-dependent fashion (dose effect,  $p < .05$ ); and that dose dependent inhibition of intestinal transit by oleate depends on the region of exposure (interaction between region and dose,  $p < .01$ ).

### EXAMPLE III

#### Case Studies Showing Successful Treatment of Diarrhea With Oleic Acid

Postgastrectomy Dumping Syndrome. The patient was a 57 year old female with a history of subtotal gastrectomy and gastrojejunostomy for peptic ulcer and gastric cancer. Symptoms on presentation of nausea, cramping pain, lightheadedness, bloating and explosive diarrhea occurring after every meal were consistent with severe dumping syndrome. These symptoms persisted despite aggressive medical therapy including the use of tincture of opium and anticholinergics. Her upper gut transit times were (min) 16 (0 g oleic acid), 99 (1.6 g oleic acid) and 108 (3.2 g oleic acid). After one pre-meal treatment with oleic acid (3.2 g mixed with 25 mL of Ensure), this patient reported immediate benefit. With continued treatment with oleic acid (3.2 g mixed with 25 mL of Ensure, gravy or other comestible emulsion three times a day, 30 minutes before breakfast, lunch and dinner), she had only rare episodes of dumping symptoms (only about once per month). Her weight increased from 118 to 130 lbs, and bowel movements decreased from 4 to 5 liquid to 2 to 3 formed bowel movements per day.

Diarrhea-Predominant Irritable Bowel Syndrome. The patient was a 39-year old male with a history of adolescent-onset, persistent diarrhea. After a routine gastrointestinal work-up failed to provide an explanation for his symptoms, he was given the diagnosis of diarrhea-predominant irritable bowel syndrome. He presented with complaints of excessive gas, postprandial bloating, diarrhea and urgency, and 3 to 7 liquid bowel movements per day. His upper gut transit times were (min) 30 (0 g oleic acid), 117 (1.6 g oleic acid) and 101 (3.2 g oleic acid). With continuing oleic acid treatment as described above, he reported his bowel frequency reduced to a single, solid bowel movement per day. He also reported complete relief from the symptoms of gaseousness, bloating and rectal urgency.

History of Ileal Resection. The patient was a 64 year old female who had chronic diarrhea since 1990, when she underwent an intestinal resective surgery to create an Indiana Pouch from her ileum to drain her right kidney. After the surgery, the patient had approximately 4 to 6 watery bowel movements per day with a 24-hour stool volume of 950 mL. At the time of presentation, she had reported a weight loss of 20 lbs over the previous 6-month

period despite greater than normal appetite and food intake. Her upper gut transit times were (min) 60 (0 g oleic acid), 68 (1.6 g oleic acid) and 148 (3.2 g oleic acid). With continuing oleic acid treatment as described above, her 24-hour stool volume decreased to 200 mL, and her stool frequency was reduced to a single solid bowel movement daily.

Short Bowel Syndrome. The patient was a 38-year old male with a thirty-year history of Crohn's disease. Five intestinal resections had resulted in a remainder of about 100 cm of small intestine and descending colon. He presented at 93 lbs; with severe difficulties with oral intake, and was readied with placement of a central line for life-long total parenteral nutrition (TPN). He was experiencing more than 20 bowel movements per day, with pain, bloating and nausea at each meal. Baseline upper gut transit time was 14 min. His transit time was prolonged to 47 and 158 min with 1.6 and 3.2 grams of oleic acid, respectively. After the patient began taking oleic acid three times a day, his stool volume decreased during the first 24-hour period from 3400 mL to 1400 mL. Over the course of 2 months of oleic acid treatment, he gained 30 lbs without TPN, and he was able to enjoy an unrestricted diet without symptoms.

A 42-year-old female patient with a history of Crohn's disease and intestinal resective surgeries developed severe diarrhea after her latest intestinal resection and ileostomy. Before treatment, her stool volume was about 1025 mL per day. With oleic acid (6.6 grams in 50 mL of Ensure), her stool volume decreased to 600 mL per day.

#### EXAMPLE IV

##### Administration of Active Lipid Increases Drug Bioavailability

Relatively rapid basal upper gut transit in Patients with Inflammatory Bowel Disease (IBD). The mean upper gut transit time for IBD patients (n=18) at 0 grams of oleic acid was  $79.1 \pm 11.0$  min., compared to  $118.7 \pm 9.8$  min for normal subjects (n = 5)( $p = 0.04$ , t-test).

Measurement of basal drug bioavailability. The hypothesis that the bioavailability of oral drug is lower in IBD patients was tested by measuring serum levels of acetaminophen after oral administration of 1000 mg of this drug in a liquid formulation. Acetaminophen was chosen, because it is absorbed rapidly and almost exclusively and entirely in the proximal intestine; it is safe in a therapeutic dose range; and is only minimally bound to plasma proteins. After subjects ingested the drug, periodic samples of blood were collected from a plastic tube inserted into a vein in each subject's arm. The blood was then analyzed spectrophotometrically for concentration of acetaminophen. Peak plasma level, time to peak concentration and area under the curve (AUC; representing the plasma acetaminophen concentration over time) were derived from these data. Relative drug bioavailability was determined by comparing AUC values. In control experiments without oleic acid, IBD patients had a smaller AUC than normal subjects, consistent with lower acetaminophen bioavailability; the mean AUC for normal patients (n = 5) was  $1438.9 \pm 208.5$ . The mean AUC for IBD patients (n=18) was  $687.3 \pm 98.2$ . ( $p < 0.05$ , t-test).

Active lipid increases upper gut transit time and drug bioavailability. The mean transit time for normal subjects (n= 5) at 0 grams of oleic acid was  $118.7 \pm 9.8$  min, at 4 grams of Oleic acid was  $136.0 \pm 15.4$  min. ( $P < 0.05$ , t-test). The mean AUC for normal subjects at 0 grams of oleic acid was  $1438.9 \pm 208.5$ ; at 4 grams of oleic acid it was  $1873.3 \pm 330.5$  ( $p < 0.05$ , t-test). The mean transit time for IBD patients (n =18) at 0 grams of oleic acid was  $79.1 \pm 11.0$  min; at 4 grams of oleic acid it was  $114.6 \pm 16.0$  min. ( $p < 0.05$ , t-test). The mean AUC for IBD patients at 0 grams of oleic acid was  $687.3 \pm 98.2$ ; at 4 grams of oleic acid it was  $1244.9 \pm 250.4$ . ( $p < 0.05$ , t-test). These data show that oleic acid slowed gut transit time and increased bioavailability of the drug in both normal and IBD groups.

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific embodiments taught hereinabove are only illustrative of the invention. It should be

understood that various modifications can be made without departing from the spirit of the invention.

66307 " 66307B0

What is claimed is:

1. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine, comprising administering to a subject in need of the treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution, absorption promoting and/or gastrointestinal transit slowing composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective to promote contact of the lipid with the subject's small intestine and, thereby prolong the residence time of an orally or enterally administered substance in the small intestine for a period of time effective to increase dissolution, bioavailability, and/or absorption of the substance therethrough.
2. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered orally.
3. The method of claim 2, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered up to about 24 hours prior to the administration of the substance.
4. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered concurrently with the substance.
5. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is a liquid or a solid.
6. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is tube-delivered.
7. The method of claim 1, wherein the active lipid comprises fully hydrolyzed fats.

8. The method of claim 1, wherein the active lipid comprises a fatty acid or a pharmaceutically acceptable salt thereof.

30 9. The method of claim 1, wherein the active lipid is:

(A) a fatty acid selected from the group of (C<sub>4</sub>-C<sub>24</sub>) saturated and unsaturated fatty acids;

(B) a pharmaceutically acceptable salt of any of (A); or

(C) a mixture of any of (A) or (B).

10. The method of claim 1, wherein the active lipid is selected from the group consisting of:

35 (A) caproic acid, caprylic acid, ~~capric~~ acid, lauric acid, myristic acid, oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, linolenic acid, trans-hexadecanoic acid, elaidic acid, columbinic acid, arachidic acid, behenic acid, eicosenoic acid, erucic acid, brassidic acid, cetoleic acid, nervonic acid, Mead acid, arachidonic acid, timnodonic acid, clupanodonic acid, or docosahexaenoic acid;

40 (B) pharmaceutically acceptable salts of any of (A); and

(C) mixtures of any of (A) or (B).

11. The method of claim 10, wherein the active lipid comprises oleic acid or a pharmaceutically acceptable ~~oleate~~ salt.

12. A method for prolonging the residence time of an orally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine, comprising administering orally to a subject in need of the treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats and mixtures thereof, in an amount and in a form effective to promote contact of the lipid with the subject's small intestine and, thereby, prolong the residence time of an orally or enterally administered substance to allow dissolution or to enhance bioavailability through the small intestine for a period of time effective to increase substance absorption therethrough.



13. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered up to about 24 hours prior to the administration of the substance.

14. The method of claim 1, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition is administered concurrently with the substance.

15. The method of claim 1, wherein the active lipid comprises fully hydrolyzed fats.

16. The method of claim 1, wherein the active lipid comprises a fatty acid or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the fatty acid or pharmaceutically acceptable salt thereof is selected from the group of (C<sub>4</sub>-C<sub>24</sub>) saturated and unsaturated fatty acids and mixtures thereof.

18. The method of claim 17, wherein the fatty acid or pharmaceutically acceptable salt thereof is selected from the group consisting of

(A) caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, linolenic acid, trans-hexadecanoic acid, elaidic acid, columbinic acid, arachidic acid, behenic acid, eicosenoic acid, erucic acid, brassidic acid, cetoleic acid, nervonic acid, Mead acid, arachidonic acid, timnodonic acid, clupanodonic acid, docosahexaenoic acid;

5

(B) a pharmaceutically acceptable salt of any of (A); and

(C) a mixture of any of (A) or (B).

19. The method of claim 1, wherein the fatty acid comprises oleic acid, a pharmaceutically acceptable oleate salt, or a mixture of either of these with other fatty acids or salts thereof.

20. The method of claim 1, wherein oral administration is by ingestion of coated or uncoated microspheres or particles, of a dispersible powder or granule formulation, of a suspension, emulsion, solution, syrup, or elixir, or of a coated or uncoated tablet, troche, capsule, caplet, or lozenge.

21. A method of treating a gastrointestinal disorder by slowing the gastrointestinal transit of an orally or enterally administered substance in a subject, comprising administering to a subject in need of the treatment at least one dose of a composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective to promote contact of the lipid with the subject's small intestine and, thereby, slow the gastrointestinal transit of an orally or enterally administered substance through the small intestine.

22. The method of claim 21, wherein the gastrointestinal transit of the substance through the small intestine is slowed for a period of time effective for absorption of the substance to occur.

23. The method of claim 22, wherein the increased absorption of the substance is associated with the slowing of the gastrointestinal transit of the substance through the small intestine.

24. A method of enhancing the digestion and absorption of orally or enterally administered nutrients and/or pharmacological agents, comprising administering to a subject in need of the treatment at least one dose of a composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective to promote the contact of the active lipid with the small intestine and, thereby, prolong the residence time and enhance the digestion and absorption of orally or enterally administered nutrients and/or pharmacological agents in the small intestine.

25. A method for reducing diarrhea, comprising administering to a subject in need of the treatment at least one dose of a composition comprising an active lipid selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats, and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective to promote contact of the active lipid with the small intestine, and prolong the residence time of the luminal contents of the small intestine and, thereby, reduce diarrhea.

26. A method of reducing the serum level of atherogenic lipids derived from an ingested substance, comprising administering to a subject in need of the treatment a composition comprising an active lipid selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed fats, and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective for promoting contact of the active lipid with small intestine, prolong the residence time in the small intestine of the ingested substance and, thereby, reduce atherogenic lipid serum levels.

27. The method of claim 26, wherein the composition is administered in an amount and in a form effective for limiting the spread and increasing the contact of the ingested substance with the proximal segment of the small intestine.

28. A method of enhancing the bioavailability of an orally ingested pharmacological agent by promoting a digestive, dissolving, absorptive, anti-atherogenic, anti-diarrheal and/or gastrointestinal transit slowing effect, comprising administering to a subject in need of the treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of saturated and unsaturated fatty acids, fully hydrolyzed lipid and mixtures thereof, in an amount of about 0.5 to about 25 grams per dose and in a form effective for promoting the contact of the lipid with the subject's small intestine, promoting an anti-atherogenic, anti-diarrheal, digestive, dissolving and/or absorptive effect and, thereby, prolonging residence time, enhancing the dissolution, bioavailability and/or absorption of an ingested pharmacological agent in the small intestine.

29. The method of claim 28, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered prior to administration of the pharmacological agent.

30. The method of claim 29, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered about 5 to about 60 minutes prior to administration of the pharmacological agent.

31. The method of claim 28, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered concurrently with the agent.

32. An anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing controlled release oral composition, comprising a dispersion in a carrier of a plurality of particles which comprise an active lipid selected from the group consisting of

(A) saturated and unsaturated fats;

(B) fully hydrolyzed fats;

(C) pharmaceutically acceptable salts of any of (A) or (B); and

(D) mixtures of any of (A), (B), or (C);

and further comprising a controlled release coating thereon, which coating upon ingestion releases the active lipid and the particles and promotes their absorption, into the proximal segment of the small intestine by effecting and sustaining gastrointestinal transit slowing, dissolution, bioavailability and/or absorption promotion and/or an anti-diarrheal and/or anti-atherogenic effect.

33. An anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing liquid enteral composition, comprising a liquid carrier and a dispersion in the carrier consisting essentially of a substance and an active lipid selected from the group consisting of

(A) saturated and unsaturated fats;

(B) fully hydrolyzed fats;

(C) pharmaceutically acceptable salts of any of (A) or (B); and

(D) mixtures of any of (A), (B), or (C), which composition upon ingestion releases the active lipid into the proximal segment of the small intestine, so as to prolong the residence time of the substance in the small intestine and, thereby, increase substance digestion, dissolution, bioavailability and/or absorption and/or anti-diarrheal and/or anti-atherogenic effect.

34. A method of enhancing the absorption of a substance in the small intestine and promoting anti-atherogenesis, anti-diarrheal, digestion, and/or dissolution, and/or slowing gastrointestinal transit, comprising administering to a subject in need of the treatment at least one dose of the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting,

and/or gastrointestinal transit slowing liquid enteral composition of claim 33, in an amount of about 0.5 to about 25 grams per dose and for a period of time effective for the active lipid to contact and be absorbed through the small intestine and, thereby, prolong the residence time, promote digestion, bioavailability and/or absorption of the substance in the small intestine and/or have an anti-diarrheal and/or anti-atherogenic effect.

35. A method of enhancing the absorption of an orally administered substance and promoting an anti-atherogenic and/or anti-diarrheal effect, and promoting digestion and dissolution, and slowing gastrointestinal transit, comprising administering to a subject in need of treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing oral composition, comprising a core comprising a substance selected from the group consisting of nutrients and pharmacological agents and a coating thereon comprising an active lipid selected from the group consisting of (A)saturated and unsaturated fatty acids; (B) pharmaceutically acceptable salts of any of (A); and (C) mixtures of any of (A) or (B), said active lipid in an amount of about 0.5 to about 25 grams per dose, effective for promoting contact of the active lipid with, and its absorption from, the proximal segment of the small intestine, thereby prolonging the residence time and increasing the digestion and absorption of the substance in the small intestine and promoting an anti-atherogenic and/or anti-diarrheal effect.

36. The method of claim 35, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

37. A method of treating a gastrointestinal disorder by slowing the gastrointestinal transit of an orally administered substance in a subject, comprising administering to a subject in need of the treatment at least one dose of a composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of

- (A)saturated and unsaturated fatty acids;
- (B) fully hydrolyzed fats;
- (C) pharmaceutically acceptable salts of any of (A); and

10 (D) mixtures of any of (A), (B) or (C), in an amount and in a form effective to promote contact of the lipid with the subject's small intestine and, thereby, slow the gastrointestinal transit of an orally or enterally administered substance through the small intestine.

38. The method of claim 37, wherein the active lipid is administered in an amount of about 0.5 to about 25 grams per dose.

39. The method of claim 37, wherein the gastrointestinal transit of the substance through the gastrointestinal tract is slowed for a period of time effective for absorption of the substance to occur.

40. The method of claim 39, wherein the increased absorption of the substance is associated with the slowing of the gastrointestinal transit of the substance through the small intestine.

41. A method of enhancing the digestion and absorption of orally administered nutrients and/or pharmacological agents, comprising administering to a subject in need of the treatment at least one dose of a composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of

5 (A) saturated and unsaturated fatty acids;  
(B) fully hydrolyzed fats;  
(C) pharmaceutically acceptable salts of any of (A); and  
(D) mixtures of any of (A), (B) or (C), in an amount and in a form effective to promote the contact of the active lipid with the small intestine and, thereby, prolong the residence time and

10 enhance the digestion and absorption of orally administered nutrients and/or pharmacological agents in the small intestine.

42. The method of claim 41, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

43. A method for reducing diarrhea, comprising administering orally to a subject in need of the treatment a composition comprising an active lipid selected from the group consisting of

(A) saturated and unsaturated fatty acids;  
(B) fully hydrolyzed fats;

5 (C) pharmaceutically acceptable salts of any of (A); and

(D) mixtures of any of (A), (B) or (C), in an amount, and in a form effective to promote contact of the active lipid with the small intestine, and prolong the residence time of the luminal contents of the small intestine and, thereby, reduce diarrhea.

44. The method of claim 43, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

45. A method of reducing the serum level of atherogenic lipids derived from an ingested substance, comprising administering to a subject in need of the treatment at least one dose of a composition comprising an active lipid selected from the group consisting of

(A) saturated and unsaturated fatty acids;

(B) fully hydrolyzed fats;

(C) pharmaceutically acceptable salts of any of (A); and

(D) mixtures of any of (A), (B) or (C), in an amount and in a form effective for promoting contact of the active lipid with small intestine, prolong the residence time in the small intestine of the ingested substance and, thereby, reduce atherogenic lipid serum levels.

46. The method of claim 45, wherein the composition is administered in an amount and in a form effective for limiting the spread and increasing the contact of the ingested substance with the proximal segment of the small intestine.

47. The method of claim 45, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

48. A method of enhancing the bioavailability of an orally ingested pharmacological agent by promoting a digestive, dissolving, absorptive, anti-atherogenic, anti-diarrheal and/or gastrointestinal transit slowing effect, comprising administering orally to a subject in need of the treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition comprising a carrier and a dispersion consisting essentially of an active lipid in the carrier, the active lipid being selected from the group consisting of

(A) saturated and unsaturated fatty acids;

(B) fully hydrolyzed fats;

10 (C) pharmaceutically acceptable salts of any of (A); and

(D) mixtures of any of (A), (B) or (C), in an amount and in a form effective for promoting the contact of the lipid with the subject's small intestine, promoting an anti-atherogenic, anti-diarrheal, digestive, dissolving and/or absorptive effect and, thereby, prolonging residence time, enhancing the dissolution, bioavailability and/or absorption of an ingested pharmacological agent  
15 in the small intestine.

49. The method of claim 48, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

50. The method of claim 48, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered prior to administration of the pharmacological agent.

51. The method of claim 48, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered about 5 to about 60 minutes prior to administration of the pharmacological agent.

52. The method of claim 48, wherein the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition is administered concurrently with the agent.

53. A method of enhancing the absorption of an orally administered substance and promoting an anti-atherogenic and/or anti-diarrheal effect, and promoting digestion and dissolution, and slowing gastrointestinal transit, comprising administering to a subject in need of treatment at least one dose of an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or  
5 absorption promoting and/or gastrointestinal transit slowing oral composition configured in a coated or uncoated tablet, capsule, or caplet form, comprising a core comprising a substance selected from the group consisting of nutrients and pharmacological agents and a coating thereon comprising an active lipid selected from the group consisting of  
10 (A) saturated and unsaturated fatty acids;  
(B) pharmaceutically acceptable salts of any of (A); and  
(C) mixtures of any of (A) or (B), in an amount effective for promoting contact of the active lipid with, and its absorption from, the proximal segment of the small intestine, thereby prolonging



the residence time and increasing the digestion and absorption of the substance in the small intestine and promoting an anti-atherogenic and/or anti-diarrheal effect.

54. The method of claim 53, wherein the active lipid is administered in an amount of about 0.5 to about 25 g/dose.

55. An enteral anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition, comprising a first component comprising an active ingredient to be absorbed through the small intestine; a second component comprising a carrier dispersible form of an active lipid selected from the group consisting of

(A) saturated and unsaturated fats;

(B) fully hydrolyzed fats;

(C) pharmaceutically acceptable salts of any of (A) or (B); and

(D) a mixture of any of (A), (B), or (C);

an enteric coating which releases the first and the second components into the proximal segment of the small intestine, where the lipid slows transit and increases digestion, dissolution and/or residence time in, and absorption through, the small intestine without significant degradation and, thereby, increases absorption of the active ingredient thereof through in the presence of the active lipid than in its absence.

56. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55, wherein the active ingredient is selected from the group consisting of nutrients and pharmacological agents.

57. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 56, wherein the nutrients are selected from the group consisting of foodstuffs, vitamins and minerals.

58. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 56, wherein the pharmacological agents are selected from the group consisting of somatostatin analogues, insulin release inhibitors, anti-diarrheal agents, antibiotics, fiber, electrolytes, analgesics, antipyretics, migraine treatment, migraine prophylaxis, antifungal agents antiviral agents, Quinolones, AIDS

therapeutic agents, anti-infectives, aminoglycosides, antispasmodics, parasympathomimetics, anti-tuberculous agents, anti-malarial agents, accines, anti-parasitic agents, cephalosporins, macrolides, azalides, tetracyclines, penicillins, anti-arthritic therapy agents, gout therapy agents, nonsteroidal anti-inflammatory agents, gold compounds, antianemic agents, antianginal agents, antiarrhythmics, anticoagulants, post-MI agents, vasodilators, beta-adrenergic blockers, calcium channel blockers, nitrates, thrombolytic agents, anticoagulants, antifibrolytic agents, hemorrhheologic agents, antiplatelet agents, vitamins, antihemophilic agents, heart failure agents, ACE inhibitors, cardiac glycosides, blood flow modifying agents, bile salts, growth promoting agents, growth suppressive agents, sympathomimetics, inotropic agents, antihypertensive agents, central alpha-adrenergic agonists, peripheral vasodilator, sympatholytics, diuretics, diuretic combinations, mineral supplements, hypolipedemic agents, acne treatments, antidiarrheal agents, antinauseants, antiemetics, antispasmodics, antiulcer, antireflux agents, appetite suppressants, appetite enhancers, gallstone-dissolving agents, gastrointestinal anti-inflammatory agents, antacids, antiflatulents, anti-gas agents, laxatives, stool softeners, digestants, digestive enzymes, enzyme supplements, alzheimer's therapy, anticonvulsants, antiparkinson agents, sedatives, benzodiazepines, benzodiazepine receptor antagonists, receptor agonists, receptor antagonists, interferons, immunosuppressive therapy, immunomodulatory agents, muscle relaxants, hypnotics, antianxiety agents, antimanic agents, antidepressants, antiobesity agents, behavior modifiers, psychostimulants, neurostimulants, abuse deterrents, anxiolytics, antipsychotics, antianaphylactic agents, antihistamines, antipruritics, anti-inflammatory agents, bronchodilators, antiasthmatic agents, cystic fibrosis therapy agents, mast-cell stabilizers, steroids, xanthines, anticholinergic agents, bioactive peptides, polypeptides, hormones, drugs acting at neuroeffector junctional sites, prostaglandins, narcotics, hypnotics, alcohols, psychiatric therapy agents, anti-cancer chemotherapy agents, drugs affecting motility, oral hypoglycemics, androgens, estrogens, nutraceuticals, herbal medications, insulin, serotonin receptor agonist, serotonin receptor antagonists, alternative medicines, amino acids, dietary supplements, analeptic agents, respiratory agents, cold remedies, cough suppressants, antimycotics, bronchodilators, constipation aids, contraceptives, decongestants, expectorants, motion sickness products, homeopathic preparations.

59. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55, further comprising an additional ingredient selected from the group consisting of carriers, ~~excipients~~, vehicles, lipid dispersants,

detergents, bile acid salts, and suspending, emulsifying, stabilizing, thickening, buffering, preserving, coloring, disintegrating, solubilizing, flavoring and sweetening agents.

60. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 59, wherein the carriers are selected from the group consisting of solid, semisolid or liquid glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, ~~keratin~~, colloidal silica, potato starch, urea, medium chain length triglycerides and dextrans.

61. A lipid dispersion, comprising the anti-diarrheal, anti-atherogenic, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55, and a lipid dispersant comprising an aqueous solution of an agent selected from the group consisting of at least one bile salt, at least one agent alkaline buffer and a detergent.

62. A lipid emulsion, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55, and a lipid dispersant comprising an agent which in the presence of the active lipid forms a two-phase emulsion.

63. A lipid suspension, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 55, and a lipid comprising a solid agent which forms a suspension with the active lipid.

64. An emulsion, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 55, emulsifiers and suspending agents; the emulsifiers and suspending agents being selected from the group consisting of gum acacia, agar, sodium alginates, bentonites, carbomers, celluloses, carrageenan, carboxymethyl celluloses, cholesterol, gelatins, octoxynol 9, oleyl alcohols, polyvinyl alcohols, povidone, propylene glycol monostearates, sodium lauryl sulfate, sorbitan esters, stearyl alcohol, tragacanth, xanthan gum, chondrus, glycerin, trolamine, coconut oil, propylene glycol, ethyl alcohol, malt, malt extracts and mixtures thereof.

65. A cellulose emulsion, comprising the emulsion of claim 62, and celluloses which are selected from the group consisting of cellulose, hydroxyethyl celluloses, hydroxypropyl celluloses, hydroxypropyl methylcelluloses, methylcelluloses and mixtures thereof.

66. An oral formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 55, and an oral carrier.

67. The oral formulation of claim 66, being in a form selected from the group consisting of capsules, coated and uncoated microspheres and particles, which may be encapsulated, coated and uncoated tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders and granules, emulsions, hard and soft capsules, syrups and elixirs.

68. A controlled release formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55, and a controlled release coating.

69. A slow release formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55 and a slow release coating.

70. A liquid enteric formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 55.

71. The liquid enteric formulation of claim 70, wherein the active ingredient comprises a dispersion of essential nutrients, pharmacological agents or mixtures thereof.

72. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 55, wherein the amount of the active lipid is about 0.5 to about 25 gram per dose.

73. An anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition formulated for oral delivery, comprising

a first component comprising an active ingredient to be absorbed through the stomach or small intestine;

- 5 a second component comprising an amount of a carrier dispersible form of an active lipid selected from the group consisting of
- (A) saturated and unsaturated fats;
  - (B) fully hydrolyzed fats;
  - (C) pharmaceutically acceptable salts of any of (A) or (B); and
  - 10 (D) a mixture of any of (A), (B), or (C).

74. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 73, wherein the amount of the active lipid is about 0.5 to about 25 gram per dose.

75. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 73, further comprising an oral carrier.

76. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 73, wherein the active ingredient is selected from the group consisting of nutrients and pharmacological agents.

77. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 76, wherein the nutrients are selected from the group consisting of foodstuffs, vitamins and minerals.

78. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 76, wherein the pharmacological agents are selected from the group consisting of somatostatin analogues, insulin release inhibitors, anti-diarrheal agents, antibiotics, fiber, electrolytes, analgesics, antipyretics, migraine treatment, migraine prophylaxis, antifungal agents, antiviral agents, Quinolones, AIDS therapeutic agents, anti-infectives, aminoglycosides, antispasmodics, parasympathomimetics, anti-tuberculous agents, anti-malarial agents, accines, anti-parasitic agents, cephalosporins, macrolides, azalides, tetracyclines, penicillins, anti-arthritic therapy agents, gout therapy agents, nonsteroidal anti-inflammatory agents, gold compounds, antianemic agents, antianginal agents,

79. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 73, further comprising an additional ingredient selected from the group consisting of carriers, ~~excipients~~, vehicles, lipid dispersants, detergents, bile acid salts, and suspending, emulsifying, stabilizing, thickening, buffering, preserving, coloring, disintegrating, solubilizing, flavoring and sweetening agents.

80. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 79, wherein the carrier is selected

from the group consisting of solid, semisolid or liquid glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides and dextrans.

81. The oral formulation of claim 73, being in a form selected from the group consisting of capsules, coated and uncoated microspheres and particles, which may be encapsulated, coated or uncoated tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders and granules, emulsions, hard and soft capsules, syrups and elixirs.

82. A controlled release formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 73, and a controlled release coating.

83. A slow release formulation, comprising the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting, and/or gastrointestinal transit slowing composition of claim 73 and a slow release coating.

84. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 73, wherein the active lipid is selected from the group consisting of ( $C_4$  to  $C_{24}$ ) fatty acids, pharmaceutically acceptable salts thereof, and mixtures of either of these.

85. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 84, wherein the active lipid is selected from the group consisting of

- (A) caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, linolenic acid, trans-hexadecanoic acid, elaidic acid, columbinic acid, arachidic acid, behenic acid, eicosenoic acid, erucic acid, brassidic acid, cetoleic acid, nervonic acid, Mead acid, arachidonic acid, timnodonic acid, clupanodonic acid, or docosahexaenoic acid;
- (B) pharmaceutically acceptable salts of any of (A); and
- (C) and mixtures of any of (A) or (B).

86. The anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 85, wherein the active lipid comprises oleic acid, a pharmaceutically acceptable oleate salt, or a mixture of either of these with other fatty acids or salts thereof.

87. A method of prolonging small intestine transit time while promoting an anti-atherogenic and/or anti-diarrheal effect and/or promoting digestion, dissolution and/or absorption, comprising administering orally to a subject in need of treatment at least one dose of the composition of claim 73, wherein the active lipid is absorbed through the stomach or proximal segment of the small intestine in undegraded form and, thereby, increases small intestine transit time and produces an anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing effect.

88. The method of claim 87, wherein the active lipid triggers at least one reflex selected from the group consisting of intestino-lower esophageal sphincter or relaxation of LES reflex, intestino-gastric feedback or inhibition of gastric emptying reflex, intestino-intestinal feedback or ileo-jejunal feedback/ileal brake reflex, jejuno-jejunal feedback/jejunal brake reflex, conversion to fed motility reflex, intestino-CNS feedback or satiety intensifying intestinal signaling reflex, intestino-pancreatic feedback or exocrine enzyme output control reflex, intestino-biliary feedback or bile flow control reflex, intestino-mesenteric blood flow feedback reflex for mucosal hyperemia control and intestino-colonic feedback, gastro-colonic reflex or colon contracting response to nutrients, in the proximal segment of the small intestine.

89. The method of claim 87, wherein the active lipid is administered in an amount of about 0.5 to about 25 grams per dose.

90. A method of treating a nutritional deficiency comprising administering to a subject afflicted with a nutritional deficiency at least one dose of the anti-atherogenic, anti-diarrheal, digestion, dissolution and/or absorption promoting and/or gastrointestinal transit slowing composition of claim 73, in an amount and in a form effective to deliver the active lipid to the subject's proximal segment of the small intestine and, thereby, increase absorption of nutrients through the subject's small intestine.



91. The method of claim 90, wherein the subject's nutritional deficiency is associated with gastrointestinal symptoms selected from the group consisting of rapid intestinal transit, dumping syndrome, diarrhea, weight loss, distention, steatorrhea, asthenia, poor bioavailability of oral drugs, and symptoms of specific nutrient deficiencies.

92. The method of claim 90, wherein the subject's nutritional deficiency is associated with a gastrointestinal disorder selected from the group consisting of post-gastrectomy syndrome, dumping syndrome, AIDS-associated chronic diarrhea, diabetes-associated diarrhea, post-vagotomy diarrhea, bariatrics surgery-associated diarrhea, short bowel syndrome, tube-feeding  
5 related diarrhea, chronic secretory diarrhea, carcinoid syndrome-associated diarrhea, gastrointestinal peptide tumors, endocrine tumors, chronic diarrhea associated with thyroid disorders, chronic diarrhea associated with bacterial overgrowth, chronic diarrhea in gastronomy, choleraic diarrhea, chronic diarrhea associated with giardiasis, antibiotic-associated chronic  
10 diarrhea, diarrhea-predominant irritable bowel syndrome, diarrhea associated with disordered gastrointestinal motility, chronic diarrhea associated with maldigestion and malabsorption, chronic diarrhea associated with idiopathic primary gastrointestinal motility disorders, chronic diarrhea associated with collagenous colitis, surgery-associated acute diarrhea, antibiotic-associated acute diarrhea and infection-associated acute infectious diarrhea.

93. The method of claim 90, wherein the bariatrics surgery-associated diarrhea comprises obesity surgeries selected from the group consisting of gastric bypass, gastroplasties and intestinal bypass.

94. The method of claim 92, wherein the short bowel syndrome is selected from the group consisting of including resection of the small intestine, radiation induced complications, Crohn's disease and infarction of the intestine associated with vascular occlusion.

95. The method of claim 90, wherein the active lipid is administered in an amount of about 0.5 to about 25 grams per dose.

[illegible]

5           The present invention further provides methods and compositions for enhancing the bioavailability and therapeutic effectiveness of pharmacologically active agents.

Parameter	Value	Unit
Temperature	25.0	°C
Pressure	1.0	atm
Flow rate	1.0	L/min
Concentration	0.1	mol/L
pH	7.0	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm
Particle size	5	μm
Mobile phase	Water/Acetonitrile	
Mobile phase ratio	90/10	
Flow rate	1.0	mL/min
Detection method	UV-Vis	
Wavelength	254	nm
Path length	1.0	cm
Sample volume	10	μL
Injection volume	1	μL
Column type	C18	
Column length	150	cm
Column diameter	4.6	mm

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Henry C. Lin, M.D.

Inventor's signature: Henry C. Lin

Date: 7/26/95

Residence: Manhattan Beach, California

Citizenship: United States

Post Office Address: 868 3rd Street  
Manhattan Beach, California 90266

PATENT  
Docket: P07 33580

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Henry C. Lin )  
Serial No.: 08/442,843 )  
Filed: May 17, 1995 )  
For: METHODS AND COMPOSITIONS FOR )  
IMPROVING DIGESTION AND )  
ABSORPTION IN THE SMALL )  
INTESTINE )

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as first class mail in an  
envelope addressed to: Commissioner of Patents and Trade  
marks, Washington, D.C. 20231 on 08/15/95

By Deborah A. Dugan Date  
Deborah A. Dugan Reg. No. 37,315  
08/15/95  
Date of Signature

BOX PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, D.C. 20231

POWER OF ATTORNEY


Sir:

I hereby appoint the following attorneys to  
prosecute the above the above-identified patent application  
and to transact all business in the Patent and Trademark  
Office connected therewith.

I authorize and request insertion of the serial  
number of the application when officially known.

STEPHEN E. REITER, Registration No. 31,192; EDWARD  
G. POPLAWSKI, Registration No. 33,439; JAMES R. BRUEGGEMANN,  
Registration No. 28,286; ROBERT A. SCHROEDER, Registration No.  
25,393; LAURENCE H. PRETTY, Registration No. 25,312; GARY A.  
CLARK, Registration No. 28,060; SHARON M. FUJITA, Registration  
No. 38,459; DEBORAH A. DUGAN, Registration No. 37,315; ROBERT  
T. RAMOS, Registration No. 37,915; and WENDY A. WHITEFORD,  
Registration No. 36,964.

[illegible]

  
Peter E. Braveman  
Vice President, Legal Affairs

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date: July 22, 1999

In re application of: Henry C. Lin  
Serial No.: Unassigned  
Filed on: Herewith  
Title: Methods and Compositions for Improving Digestion and Absorption in the Small Intestine

Examiner: Unassigned  
Group Art Unit: --

## ASSOCIATE POWER OF ATTORNEY

Assistant Commissioner for  
Patents  
Washington, D. C. 20231

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL" POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1-10 ON THE DATE INDICATED BELOW AND IS ADDRESSED TO BOX NEW PATENT APPLICATION, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Date of Deposit: July 22, 1999

Name of Person Mailing Paper: JOHN TRIVINO

  
Signature of Person Mailing Paper


Dear Sir:

I hereby appoint Nisan A. Steinberg, Ph.D., Registration No. 40,345, associate attorney with full powers to prosecute this application, to make alterations and amendments therein, and to transact all business in the United States Patent and Trademark Office connected herewith.

Please direct all correspondence to Edward G. Poplawski, Esq. at the above address, and please direct all telephone calls to Nisan A. Steinberg, Ph.D. at 213/622-7700.

Respectfully submitted,

PRETTY, SCHROEDER & POPLAWSKI, P.C.

  
Edward G. Poplawski  
Registration No. 33,439

PRETTY, SCHROEDER & POLAWSKI, P.C.

444 South Flower Street, 19th Floor

Los Angeles, California 90071-2909

Ofc: 213/622-7700

Fax: 213/489-4210

S:\AWE\CEDAR\43085POA.ASC